Immunoglobulin Market 2020 Global Industry Analysis by Size, Share, Trends and Growth Forecast to 2026, is latest depth analysis research report published on “Global Immunoglobulin Market” by Fortune Business Insights. Report segments comprehensive information about Immunoglobulin Market By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form (Liquid, Lyophilized), By End User (Hospitals, Clinics, Homecare), and Regional Forecast 2018-2025.
“Immunoglobulin” Market 2020 report presents a comprehensive assessment of the global pre filled syringes market by offering valuable insights, Immunoglobulin types, facts, industry-related information, and historical data. Several methodologies and approaches are adopted to make meaningful assumptions and views. Furthermore, the report offers a detailed analysis and information as per Immunoglobulin manufacturers, market segments helping our readers to get a comprehensive overview of the global market. Several players are planning to focus on developing cost-effective products or services, aiming to maintain a strong foothold in the market.
According to report Global Immunoglobulin Market size is expected to reach USD 18,378.0 million by 2025 exhibiting a CAGR of 7.0% during the forecast period. The increasing diagnosis rates owing to escalating awareness regarding the treatment of immunoglobulins will have a tremendous effect on the market.
Immunoglobulin Companies Analyzed In Report:
- Shire (Takeda Pharmaceutical Company Limited)
- CSL Behring
- Grifols, S.A.
- Kedrion S.p.A
- Bio Products Laboratory Ltd.
- Biotest AG
- China Biologic Products Holdings, Inc.
- LFB SA
- Shanghai RAAS Blood Products Co., Ltd.
Immunoglobulin Market Analysis:
The global immunoglobulin market size is expected to reach USD 18,378.0 million by 2025 exhibiting a CAGR of 7.0% during the forecast period. The increasing diagnosis rates owing to escalating awareness regarding the treatment of immunoglobulins will have a tremendous effect on the market during the forecast period, states Fortune Business Insights in a report, titled “Immunoglobulin Market Size, Share and Industry Analysis By Route of Administration (Intravenous (IV), Subcutaneous (SC)), By Indication (Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome (GBS), Immune Thrombocytopenic Purpura (ITP), Multifocal Motor Neuropathy (MMN)), By Form (Liqui, Lyophilized), By End User (Hospitals, Clinics, Homecare), and Regional Forecast 2018-2025” the market size stood at USD 10,750.0 million in 2017.
Highlights of the Report
- Elaborative overview of the industry outlook;
- 360-degree analysis of the factors driving and restraining the market;
- Careful study of the different market segments; and
- Detailed research into the regional and competitive dynamics influencing the market growth.
The Immunoglobulin market analysis offers a 360-degree overview of the market with a major emphasis on growth drivers, restraints, challenges, and opportunities. The report lists various segments of the market. It also provides a competitive landscape with base and forecast figures and the CAGR. The report also lists the names of significant players and their key strategies such as mergers and acquisitions, product launches, investments in research and development of clinical trials, company collaborations, and other Immunoglobulin market trends.
Introduction of Advanced Therapeutic to Augment Growth
The launch of novel advanced drugs such as CUVITRU and BIVIGAM by Shire (Takeda Pharmaceutical Company Limited) and ADMA Biologics Inc., respectively will impel manufactures to innovative drugs and give competition to the rival companies, which, in turn, will spur opportunities for the market. The increasing adoption of immunoglobulin therapy as the first line of treatment for the primary immunodeficiency and other rare immunological and neurological diseases will be a critical factor in promoting the growth of the market. The growing focus on the diagnosis of immune disorders will foster the healthy growth of the market. The increasing prevalence of numerous viruses and diseases has led to pre-diagnosis, which, in turn, will augur well for the market. The growing efficiency of immunoglobulin as an effective treatment option for several diseases such as primary immunodeficiency and chronic inflammatory demyelinating polyneuropathy (CIDP) will positively enable speedy expansion of the market in the foreseeable future.
Regional Market Overview:
Rising Patient Population to Aid Expansion in North America
The market in North America generated a revenue of US$ 6,291.5 Mn in 2017 and is and is predicted to remain dominant during the forecast period. The growth in the region is attributed to the acceptance of immunoglobulin as a first line of treatment for many critical immune disorders. The increasing number of patients and the growing demand for novel therapies will further aid the growth of the market in the region. Asia Pacific is predicted to hold the largest share in the market owing to the demand for intravenous (IV) in the developing nations. The increasing healthcare expenditure and rising investment for advanced immunoglobulins will further enable growth in the region. The Middle and Africa is likely to expand in the forthcoming years owing to the developing healthcare infrastructure in the region.
Regional analysis is another highly comprehensive part of the research and analysis study of the global market presented in the report. This section sheds light on the sales growth of different regional and country-level markets. For the historical and forecast period to 2024, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.
May 2019: FDA announced the approval of prior approval supplement (PAS) for ADMA Biologics.
May 2018: Kedrion S.p.A and Kamada announced the launch of KEDRAB, an immunoglobulin aimed at the treatment of rabies.
The Immunoglobulin Market report examines competitive scenario by analyzing key players in the market. The company profiling of leading market players is included this report with Porter’s five forces analysis and Value Chain analysis. Further, the strategies exercised by the companies for expansion of business through mergers, acquisitions, and other business development measures are discussed in the report. The financial parameters which are assessed include the sales, profits and the overall revenue generated by the key players of Market.
Table of Content:
- Scope Of The Study
- Research Objective
- Primary Research
- Secondary Research
- Market Size Estimation
- Macroeconomic Indicators
- Technology Trends & Assessment
Market Factor Analysis
- Porter’s Five Forces Analysis
- Bargaining Power Of Suppliers
- Bargaining Power Of Buyers
- Threat Of New Entrants
- Threat Of Substitutes
- Intensity Of Rivalry
- Value Chain Analysis
- Investment Feasibility Analysis
- Pricing Analysis
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune -411045, Maharashtra, India.
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245